GHRP-6

GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide that binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons to stimulate release of endogenous growth hormone. It was one of the earliest GHRPs characterized in the foundational Bowers lab work of the 1980s. Like endogenous ghrelin, GHRP-6 both releases GH and stimulates appetite through the hypothalamic arcuate nucleus NPY/AgRP neurons. It is not FDA-approved; research and off-label use is via SC injection, typically 100-200 mcg 2-3 times daily fasted. GHRP-6 synergizes strongly with GHRH analogs like sermorelin and CJC-1295 to produce 3-5x amplified GH pulses.

Both are hexapeptide GHS-R1a agonists with similar GH-release potency, but they differ in their cross-pathway effects. GHRP-6 produces markedly stronger appetite stimulation for a given GH response — this can be a feature for bulking or recovery from illness, or a bug for users trying to maintain a caloric deficit. GHRP-2 produces slightly higher GH pulse amplitude at equivalent doses with less pronounced appetite effect. Both elevate cortisol and prolactin modestly. The practical decision: if appetite stimulation is desired, GHRP-6; if GH potency is the priority and appetite stimulation is unwanted, GHRP-2; if the cleanest possible pharmacology is the goal, ipamorelin.

Standard subcutaneous protocol is 100-200 mcg per injection, 2-3 times daily, dosed in the fasted state (2-3 hours after last meal). Beginners start at 100 mcg twice daily (pre-breakfast and pre-bed) and titrate up. Intermediate users typically dose 100-150 mcg three times daily (pre-breakfast, pre-training, pre-bed). The single-injection ceiling is approximately 300 mcg — above this, GHS-R1a receptor saturation prevents additional GH release. Always dose fasted and plan meals around injection timing to make the appetite effect productive rather than destructive to your macro targets.

Yes — this is the signature pharmacologic effect. GHRP-6 produces some of the most pronounced appetite stimulation of any peptide in common use, noticeable within 30-60 minutes of injection. This is why GHRP-6 is often preferred over GHRP-2 or ipamorelin during bulking phases, recovery from illness, or in patients with cachexia/anorexia. It is also why GHRP-6 is a poor choice for users trying to maintain a caloric deficit — the appetite signal directly antagonizes the deficit and often proves unsustainable. Meal planning is critical: have a planned meal ready within 30-60 minutes of each injection to make the hunger productive.

Yes. The most pharmacologically meaningful stack is GHRP-6 + GHRH analog (sermorelin, CJC-1295 no-DAC, or tesamorelin) in the same injection 2-3 times daily — this produces 3-5x amplified GH pulses via the GHRH × ghrelin intracellular synergy principle (Bowers 1991). GHRP-6 also stacks well with BPC-157 and TB-500 for tissue repair during bulking phases, and with testosterone replacement for additive anabolic effects in hypogonadal men. Avoid stacking with other GHS-R1a agonists (GHRP-2, ipamorelin, hexarelin, MK-677) — they are mechanistically redundant. Also avoid stacking with GLP-1 agonists during deficit phases because the appetite signals actively oppose each other.

The most common effects are strong appetite stimulation (often dramatic), flushing and warmth in the face immediately post-injection, injection site reactions, and vivid dreams with bedtime dosing. Less common effects include mild transient cortisol elevation (+15-25%), mild prolactin elevation, fluid retention in the first 2-3 weeks, mild headache, and rare nausea. Chronic use can produce modest insulin resistance, GHS-R1a receptor desensitization (mitigated by cycling), and cumulative weight gain if caloric intake is not managed. Like all GH-axis interventions, the sustained IGF-1 elevation carries theoretical cancer concerns and contraindications around active malignancy.

GHRP-6 is not FDA-approved for any indication in the United States. It is sold in the research-peptide market under research-only classification. Users should understand this legal context, source from vendors with third-party purity testing, and ideally work with a practitioner familiar with peptide therapy. Some 503B compounding pharmacies include GHRP-6 in their offerings for physician-supervised off-label use. The lack of FDA approval reflects the commercial pathway the original sponsors did not pursue, not a specific safety concern — the research literature supports an acceptable short-term safety profile at standard doses. See our best vendors guide for reliable sources.

They target the same receptor but have fundamentally different cross-pathway profiles. GHRP-6 has strong appetite stimulation, modest cortisol and prolactin elevation, and 15-30 minute half-life. Ipamorelin has minimal appetite effect, minimal cortisol/prolactin cross-reactivity, and ~2 hour half-life. For bulking phases, post-illness recovery, or users who want to eat more, GHRP-6 is the better fit. For cutting phases, chronic daily use, or users with baseline anxiety/HPA concerns, ipamorelin is the cleaner choice. Many practitioners use GHRP-6 during anabolic phases and switch to ipamorelin for maintenance or cut phases. See ipamorelin for detailed comparison.

Single-injection GH elevation is measurable within minutes, peaks at 15-30 minutes, and returns to baseline by 90-120 minutes. The appetite effect is usually noticeable within 30-60 minutes. Clinically meaningful body composition effects take 8-16 weeks of consistent dosing. IGF-1 stabilizes at new elevated setpoint around weeks 4-6. Lean body mass changes become detectable at weeks 8-12. For bulking use, the appetite and caloric intake effects are immediate and become the primary driver of weight and muscle gains when caloric surplus is maintained. Sleep quality improvements (slow-wave sleep, vivid dreams) typically appear within the first 1-2 weeks of bedtime dosing.

Yes — bulking is arguably GHRP-6's best use case. The appetite stimulation facilitates the higher caloric intake required for lean mass gains, while the GH/IGF-1 amplification enhances anabolic signaling. A classical bulk-phase stack is GHRP-6 150-200 mcg + CJC-1295 no-DAC 100-150 mcg three times daily fasted, combined with disciplined progressive overload training, high-protein eating (1g/lb bodyweight minimum), and quality sleep. BPC-157 and TB-500 are often layered for connective tissue and soft tissue support under the increased training load. Plan 12-16 week phases and transition to ipamorelin or GHRP-2 during subsequent cut or maintenance phases to avoid the hunger effect working against you.